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Abstract
Alterations of activity and expression in tricarboxylic acid (TCA) cycle key enzymes have
been indicated in several malignancies, including hepatocellular carcinoma (HCC). They
play an important role in the progression of cancer. However, the impact of single nucleotide
polymorphisms (SNPs) in genes encoding these key enzymes on the recurrence of HCC
has not been investigated. In this study, we genotyped 17 SNPs in genes encoding TCA
cycle key enzymes and analyzed their association with recurrence-free survival (RFS) in a
cohort of 492 Chinese HCC patients by Cox proportional hazard model and survival tree
analysis. We identified 7 SNPs in SDHC, SDHD, FH, and IDH2 genes to be significantly as-
sociated with the RFS of HCC patients. Moreover, all these SNPs were associated with the
early recurrence (within 2 years after surgery) risk of diseases. Cumulative effect analysis
showed that these SNPs exhibited a dose-dependent effect on the overall and early recur-
rence. Further stratified analysis suggested that number of risk genotypes modified the pro-
tective effect on HCC recurrence conferred by transcatheter arterial chemoembolization
treatment. Finally, the survival tree analysis revealed that SNP rs10789859 in SDHD gene
was the primary factor contributing to HCC recurrence in our population. To the best of our
knowledge, we for the first time observed the association between SNPs in genes encoding
TCA cycle key enzymes and HCC recurrence risk. Further observational and functional
studies are needed to validate our findings and generalize its clinical usage.
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Introduction
Hepatocellular carcinoma (HCC) is one leading cause of cancer death worldwide[1]. The cur-
rent curative therapies for HCC are limited to early stage diseases with first-line treatments of
surgical resection and liver transplantation. However, the recurrence and metastasis occur fre-
quently after curative surgical treatment [2]. It has been estimated that the 5-year recurrence
rate is frequently higher than 70% in HCC patients with early stage disease after curable treat-
ments such as surgical resection and ablation, although significant low recurrence rate (<15%)
can be obtained by treatment with liver transplantation [3]. In current clinical settings, progno-
sis assessment and recurrence prediction after surgical treatment in HCC patients are mainly
based on clinicopathological characteristics, such as stages according to the Barcelona Clinic
Liver Cancer (BCLC) or TNM staging system [3,4]. However, the lack of sensitivity for predict-
ing individual patient’s prognosis led to the necessity for an improved prediction system by in-
troducing tumor biomarkers [5]. Unfortunately, specific biomarkers that can be validated and
expended to clinical settings are still lacking and urgently needed.
The tricarboxylic acid (TCA) cycle is a core pathway for the metabolism of sugars, lipids,
and amino acids in the mitochondria [6]. The fundamental role of TCA cycle is to constantly
oxidize the acetyl moiety of acetyl-CoA to CO2 and to generate NADH and FADH2 which feed
electrons to the respiratory chain for ATP generation [7]. Three enzymes, succinate dehydroge-
nase (SDH), fumarate hydratase (FH), and isocitrate dehydrogenase (IDH), are well recognized
as key players in maintaining the physiological role of TCA cycle inside the mitochondria. Re-
cent studies have suggested that the malfunctions of TCA cycle, especially the abnormally al-
tered activities of three key enzymes caused by the genetic mutations, are associated with many
cancer initiation and progression[8–11]. For example, it has been reported that the succinate-
producing activity, which is usually used as an indicator for metabolizing activity of TCA cycle
in mitochondria, is significantly higher in the HCC tumor tissues than that in non-tumor tis-
sues [11].
Single nucleotide polymorphism (SNP) is the most common form of genetic variations, and
emerging evidences have shown that SNPs may be used as promising surrogate biomarkers of
individual genetic background to predict therapeutic responses and prognosis in cancer pa-
tients. And the candidate individual SNP assay is easy to perform in most of clinical laboratory
by probe-based Real-time quantitative PCR method [12]. However, up to date, there is no
study to investigate the effect of SNPs in the genes encoding TCA cycle key enzymes on HCC
recurrence. In this study, we sought to evaluate the associations between functional SNPs in
genes encoding three TCA cycle key enzymes (SDH, FH, and IDH) and HCC recurrence in a
hospital-based Chinese patient cohort.
Materials and Methods
Study population
The study subjects were recruited from Eastern Hepatobiliary Surgery Hospital affiliated to
The Secondary Military Medical University (SMMU) in Shanghai and Xijing Hospital affiliated
to The Fourth Military Medical University (FMMU) in Xi’an, China. Between January 2009
and January 2012, a total of 518 Han Chinese patients diagnosed with primary HCC were in-
cluded in the initial cohort. HCC was diagnosed based on the National Comprehensive Cancer
Network clinical practice guidelines in oncology. All patients had no history of other cancers.
All patients received surgery within 2 months after diagnosis and without any anticancer treat-
ment before surgery. In this present study, we finally analyzed 492 patients after excluding 26
patients, which including 3 patients with incomplete clinical data and 23 patients died within 1
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month post-surgery. This study was approved by the Ethic Committee of FMMU and SMMU,
and a signed informed consent was obtained from each participant.
Data collection and follow-up
Demographic variables including age, gender and clinical data such as serum HBsAg status,
serum AFP level, tumor characteristics, and disease stages were collected through medical
chart review and consulting with the treating physicians by trained clinical specialists. Patients
were followed up 1 month after surgical resection treatment, and the follow-up information
was updated at 6-month intervals through onsite interviews, direct calling, or medical chart re-
view. The last follow-up data in this study was obtained in January 2013.
Selection and genotyping of SNPs
Blood sample (5mL) was obtained from each participant before any treatment for genomic
DNA extraction using E.Z.N.A. Blood Midi Kit (Omega Bio-Tek, Norcorss, GA, USA). The
candidate functional SNPs in TCA cycle key enzymes were selected by a set of web-based SNP
selection tools (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm). The SNP selection criteria
were as following: 1) potential functional SNPs should have minor allele frequency 5% in
Han Chinese population in the HapMap database; 2) SNPs should be located in miRNA bind-
ing sites of the 3’ untranslated region (3’UTR), in the transcription factor binding site of 5’ un-
translated region (5’UTR), in the mRNA splice site, or in exons; 3) If there were multiple
candidate SNPs within the same haploid block and the linkage disequilibrium (LD) coefficient
r2> 0.8, only one SNP was included. Finally, a total of 17 potential functional SNPs in SDH
(including subunits of SDHA, SDHB, SDHC, and SDHD), FH, and IDH (including subunits of
IDH1 and IDH2) genes were identified. SNPs were genotyped in blood DNA which can repre-
sent those from the liver tissues using the Sequenom iPLEX platform (Sequenom Inc., San
Diego, CA, USA) and laboratory persons who conducted the genotyping assays were blinded
to patients’ information. Quality controls were implemented in each assay for genotyping and
SNP with call rate>98% was included for further analysis. The detailed information of candi-
date SNPs and genotyping results were listed in S1 Table.
Statistical analysis
The primary endpoint of this study was recurrence-free survival (RFS). Recurrence was defined
as the regrowth of tumor in the original organ or different organ after the surgical treatment,
which was diagnosed based on the combined examinations of abdominal imaging findings
(MRI and CT) and laboratory examinations. RFS was defined as the time from surgical treat-
ment to local recurrence or distant metastasis. All patients without recurrence or lost during the
follow-up were censored for the analysis. The secondary endpoints were early recurrence, which
occurred within 2 years after surgical treatment, and late recurrence, which occurred more than
2 years after surgery. The association between single SNP and HCC recurrence risk was estimat-
ed by hazard ratios (HRs) generated from Cox proportional hazards regression model using
multivariate analysis. To reveal whether the significant results in our analysis were false positive
due to multiple SNPs were analyzed, the q value that reflects the false discovery rate was used to
adjust the significance for individual SNP by q value package implemented in the R software.
Kaplan-Meier survival curve and log-rank test were used to assess the differences in RFS among
different patient groups. Cumulative effect was evaluated by the combination of risk genotypes
identified from the main analyses of the individual SNPs, in which the risk genotype was defined
as that genotype carried by patient group who had significant worse clinical outcomes in the
survival analyses. All above mentioned statistical analyses were performed using the IBM SPSS
SNPs in TCA Genes and Early Recurrence of HCC
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Statistics 19.0 software (IBM). Survival tree analysis was used to determine the higher-order
gene-gene interactions using the STREE program (http://masal.med.yale.edu/stree/) in which
recursive-partitioning was used to identify subgroups of individuals at higher risk. All P values
were 2-sided, and P< 0.05 was considered as statistical significance.
Results
Characteristics of the study population
As shown in Table 1, 295 patients developed recurrence during the median follow-up time of 22.7
months (range, 1.6–48.3 months). There were 60 patients lost during the follow-up duration and
Table 1. Characteristics distribution of study population by recurrence.
Variables No recurrence (%), n = 197 Recurrence (%), n = 295 P value*
Age, mean (SD) 53.5 (10.7) 51.7 (10.7) 0.064
Gender
Female 33 (16.8) 34 (11.5)
Male 164 (83.2) 261 (88.5) 0.098
HBsAg
Negative 19 (9.6) 27 (9.2)
Positive 178 (90.4) 268 (90.8) 0.854
Serum AFP (ng/ml)
< 200 126 (64.0) 138 (46.8)
 200 71 (36.0) 157 (53.2) 1.8 × 10-4
Tumor size (cm)
< 5 103 (52.3) 106 (35.9)
 5 94 (47.7) 189 (64.1) 3.2 × 10-4
Tumor number
Single 176 (89.3) 220 (74.6)
Multiple 21 (10.7) 75 (25.4) 5.1 × 10-5
Tumor differentiation
Well and moderate 82 (41.6) 65 (22.0)
Poor 115 (48.4) 230 (78.0) 3.3 × 10-6
TNM stage
Stage I + II 179 (90.9) 215 (72.9)
Stage III + IV 18 (9.1) 80 (27.1) 9.9 × 10-7
BCLC stage
A 172 (87.3) 190 (64.4)
B 15 (7.6) 47 (15.9)
C 10 (5.1) 58 (19.7) 6.5 × 10-8
PVTT status
Negative 192 (97.5) 247 (83.7)
Positive 5 (2.5) 48 (16.3) 1.5 × 10-6
First-line treatment
Surgery only 114 (57.9) 193 (65.4)
Surgery + TACE 83 (42.1) 102 (34.6) 0.090
*P values were compared by chi-square test for categorical variables and Student’s t test for continuous variable.
Abbreviations: AFP, α-fetal protein; BCLC, Barcelona Clinic Liver Cancer; HBsAg, hepatitis B virus surface antigen; SD, standard deviation; PVTT, portal
vein tumor thrombus; TACE, transcatheter arterial chemoembolization
doi:10.1371/journal.pone.0124471.t001
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censored for further analysis, and the rate of follow-up lost was 12.2%. When compared with
those in reference group, there was a significantly higher risk of recurrence in patients with higher
serum AFP (P = 1.8 × 10-4), larger tumor size (P = 3.2 × 10-4), multiple tumors (P = 5.1 × 10-5),
poor differentiated tumors (P = 3.3 × 10-6), advanced TNM stages (P = 9.9 × 10-7) and BCLC
stages (P = 6.5 × 10-8), and port vein tumor thrombus (P = 1.5 × 10-5).
Associations between individual SNPs and RFS of HCC patients
We assessed the association of each individual SNP with the recurrence of HCC under domi-
nant, recessive and additive models, and presented the results as best-fitting model with the
smallest P value. As shown in Table 2, SNPs rs12064957 and rs3935401 in SDHC gene were sig-
nificantly associated with increased HCC overall recurrence risk under recessive (HR = 2.01,
95%CI 1.02–3.96, P = 0.044) and additive (HR = 1.24, 95%CI 1.00–1.53, P = 0.049) models, re-
spectively. All three SNPs in SDHD gene were significantly associated with the increased HCC
recurrence risk under dominant model. However, these three SNPs in SDHD gene exhibited
strong LD coefficient r2> 0.8 (S1 Fig). Therefore, we only included the most significant SNP
rs10789859 in further analyses. SNPs rs1414493 in FH gene and rs11540478 in IDH2 gene
were significantly associated with the decreased HCC overall recurrence risk under dominant
(HR = 0.77, 95%CI 0.61–0.97, P = 0.030) and recessive (HR = 0.25, 95%CI 0.09–0.68,
P = 0.007) models, respectively. We further evaluated the effects of individual SNPs on early re-
currence of patients and found very similar results as the overall recurrence analysis. Further-
more, all the significant SNPs had q values smaller than 0.12, suggesting relatively low
probability of false positive findings in our study (Table 2).
Cumulative effects of risk genotypes on HCC recurrence
To evaluate the cumulative effect of multiple SNPs on HCC recurrence risk, we combined the
risk genotypes of significant individual SNPs and analyzed the associations with HCC recur-
rence risk by multivariate Cox proportional hazards model. According to the significant results
of best-fitting model in Table 2, the risk genotypes of 5 selected significant SNPs were defined
as following: SDHC:rs12064957(VV), SDHC:rs3935401(WV+VV), SDHD:rs10789859(WV
+VV), FH:rs1414493(WW), IDH2:rs11540478(WW+WV). In the overall recurrence analysis,
the significantly increased recurrence risks of HCC were observed in patients with 2 risk geno-
types (HR = 2.04, 95%CI 1.37–3.04, P = 4.2 × 10-4) and in patients with 3 risk genotypes
(HR = 2.55, 95%CI 1.72–3.79, P = 3.1 × 10-6), when comparing to those with 1 risk genotype.
The cumulative effects of combined risk genotypes exhibited a significant dose-dependent
manner with P for trend of 3.1 × 10-6 (Fig 1A, right panel). Kaplan-Meier curves significantly
distinguished the patients with> 1 risk genotypes from those with 1 risk genotype (log-rank
P = 3.9 × 10-4) by overall recurrence-free survival analysis (Fig 1A, left panel). There were very
similar results on the cumulative effects of combined risk genotypes in early recurrence-free
survival analysis (Fig 1B).
Stratified and joint analyses for cumulative effects of risk genotypes on
early recurrence of HCC
We conducted the stratified analyses to assess the cumulative effects on early recurrence rate in
different strata of host variables by Kaplan-Meier curves. As shown in S2 Fig, HCC patients
with 2 risk genotypes had significantly higher early recurrence rates than those with< 2 risk
genotypes in the strata of subgroups without TACE treatment (Log rank P = 2.2 × 10-5) and
with diseases at early stages (I+II) (Log rank P = 7.4 × 10-5), but not in strata of subgroups with
TACE treatment (Log rank P = 0.167) and with TNM stage III or IV diseases (Log rank
SNPs in TCA Genes and Early Recurrence of HCC
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P = 0.222) (S2 Fig, right panels). In addition, we further conducted the joint analyses to reveal
if the major characteristics will have significant interaction with the number of risk genotypes
on HCC early recurrence. As shown in S2 Table, the significant increased HCC early recur-
rence risk were observed in patients with the combinations of higher risk genotypes and higher
serum AFP level advanced tumor stage, poor tumor differentiation, or no TACE treatment.
Significant interactions were exhibited between the genetic factor and clinical parameters with
P for interaction< 0.001.
Stratified analysis for effect of TACE treatment on early recurrence of
HCC by risk genotypes
We further evaluated the protective effects of TACE treatment on HCC patients’ early recur-
rence stratified by combined risk genotypes. Kaplan-Meier analysis showed that TACE
Table 2. Association of polymorphisms in TCA cycle genes with recurrence in HCC patients.
Genesymbol SNP Overall recurrence Early recurrence Late recurrence
Best
ﬁtting
model
HR (95%
CI)*
P value q value Best
ﬁtting
model
HR (95%
CI)*
P value q value Best
ﬁtting
model
HR (95%
CI)*
P=value q value
SDHA rs13173911 REC 0.79
(0.45–1.40)
0.424 0.551 REC 0.86
(0.49–1.51)
0.590 0.669 NA NA NA NA
rs2864963 REC 0.70
(0.46–1.06)
0.089 0.189 REC 0.73
(0.48–1.12)
0.154 0.291 REC 0.80
(0.33–1.91)
0.614 0.878
SDHB rs3754509 REC 1.11
(0.81–1.53)
0.515 0.584 REC 1.20
(0.87–1.65)
0.266 0.411 REC 1.09
(0.46–2.57)
0.853 0.910
SDHC rs12064957 REC 2.01
(1.02–3.96)
0.044 0.119 REC 2.25
(1.14–4.45)
0.019 0.065 ADD 0.65
(0.22–1.95)
0.438 0.878
rs4131826 ADD 0.92
(0.77–1.12)
0.416 0.551 ADD 0.94
(0.77–1.14)
0.502 0.656 REC 0.67
(0.26–1.72)
0.409 0.878
rs3935401 ADD 1.24
(1.00–1.53)
0.049 0.119 ADD 1.26
(1.01–1.56)
0.038 0.100 REC 1.04
(0.42–2.61)
0.928 0.928
SDHD rs544184 DOM 1.56
(1.22–2.01)
4.8 × 10–4 0.003 DOM 1.62
(1.25–2.11)
3.0 × 10–4 0.002 REC 1.18
(0.49–2.82)
0.710 0.878
rs7121782 DOM 1.59
(1.24–2.05)
3.0 × 10–4 0.003 DOM 1.65
(1.27–2.15)
1.8 × 10–4 0.002 REC 1.18
(0.49–2.82)
0.709 0.878
rs10789859 DOM 1.60
(1.25–2.06)
2.3 × 10–4 0.003 DOM 1.67
(1.28–2.18)
1.3 × 10–4 0.002 REC 1.14
(0.48–2.72)
0.768 0.878
FH rs12071124 DOM 0.91
(0.70–1.17)
0.454 0.551 DOM 0.92
(0.70–1.21)
0.547 0.664 REC 0.75
(0.30–1.89)
0.548 0.878
rs7530270 DOM 0.90
(0.69–1.16)
0.403 0.551 DOM 0.91
(0.69–1.19)
0.470 0.656 REC 0.81
(0.32–2.05)
0.655 0.878
rs1414493 DOM 0.77
(0.61–0.97)
0.030 0.102 DOM 0.78
(0.61–0.99)
0.041 0.100 DOM 0.64
(0.27–1.56)
0.329 0.878
IDH1 rs12478635 DOM 0.87
(0.67–1.11)
0.263 0.447 DOM 0.84
(0.65–1.09)
0.198 0.337 REC 1.78
(0.59–5.42)
0.307 0.878
IDH2 rs11540478 REC 0.25
(0.09–0.68)
0.007 0.030 REC 0.21
(0.07–0.67)
0.008 0.034 REC 1.17
(0.47–2.92)
0.733 0.878
rs4283211 DOM 0.94
(0.74–1.19)
0.604 0.604 REC 1.12
(0.71–1.77)
0.635 0.675 REC 0.44
(0.18–1.10)
0.078 0.878
rs11632348 DOM 0.93
(0.74–1.18)
0.557 0.592 REC 1.06
(0.67–1.67)
0.819 0.819 REC 0.51
(0.20–1.26)
0.143 0.878
rs4932158 REC 0.64
(0.36–1.12)
0.118 0.223 REC 0.61
(0.34–1.09)
0.097 0.206 REC 0.83
(0.29–2.36)
0.730 0.878
*HR was adjusted for age, gender, HBsAg status, serum AFP level, TNM stage, tumor differentiation and treatment.
Abbreviations: ADD, additive model; DOM, dominant model; REC, recessive model; TFBS, transcription factor binding site.
Signiﬁcant P values (< 0.05) were bolded. And q values were calculated by multiple comparison q tests.
doi:10.1371/journal.pone.0124471.t002
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treatment significantly increased the early recurrence-free survival time in all patients with log
rank P value of 4.7 × 10-4 (Fig 2A). Interestingly, there was no protective effect conferred by
TACE treatment in subcohort of patients with less than 2 risk genotypes (log rank P = 0.622)
(Fig 2B). However, the significant protective effect conferred by TACE treatment was remained
in subcohort of patients with equal to or more than 2 risk genotypes (log rank P = 6.6 × 10-5)
(Fig 2C).
Higher order gene-gene interactions and early recurrence of HCC
We explored the higher order gene-gene interactions to reveal whether complex interactions
among these SNPs could potentially predict the patient’s recurrence by survival tree analysis.
Among 7 significant SNPs in the early recurrence analysis, we identified 2 SNPs, SDHD:
rs10789859 and FH:rs1414493, which resulting in 3 terminal nodes with different early RFS
time (Fig 3). The initial split on the survival tree was due to SDHD:rs10789859 (Node 3),
Fig 1. Cumulative effects of risk genotypes. A) Overall recurrence free survival; B) Early recurrence free survival. Cumulative effects of risk genotypes
groups were assessed by Kaplan-Meier curves (left panels) and estimated using Cox proportional hazards model by multivariate analysis (right panels).
Individual SNPs with significant P values <0.05 were included to categorize the risk genotype groups.
doi:10.1371/journal.pone.0124471.g001
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suggesting that this SNP was the primary risk factor contributing to the RFS difference in this
HCC population. Patients in the reference group (Node 1) were composed of individuals with
2 favorable genotypes, including wild-type of SDHD:rs10789859 and variant-containing geno-
types of FH:rs1414493. Comparing to the reference group, patients carrying wild-type of FH:
rs1414493 (Node 2) and variant-containing genotypes of SDHD:rs10789859 (Node 3) exhib-
ited significant increased early recurrence risk with HR of 1.92 (95%CI 1.23–3.00) and 2.22
(95%CI 1.55–3.16), respectively (Fig 3A). Kaplan-Meier curve analysis also indicated the signif-
icantly decreased early RFS time in Node 2 and Node 3 patients, comparing to the reference
group (Node 1), with log rank P value of 0.001 (Fig 3B).
Furthermore, we separated the primary cohort (n = 487) to FMMU cohort (n = 190) and
SMMU cohort (n = 297) based on the hospital sites, and validated the survival tree analysis re-
sults by grouping the patients according to the survival tree model using multivariate Cox
Fig 2. Modified effects of TACE treatment on HCC recurrence stratified by the number of risk genotypes. A) In all patients; B) In patients with less than
2 risk genotypes; C) In patients with equal to or more than 2 risk genotypes.
doi:10.1371/journal.pone.0124471.g002
Fig 3. Potential higher order gene—gene interactions among TCA pathway polymorphisms. A) Tree
structure identifying subgroups of patients with different genetic backgrounds; B) Kaplan—Meier survival
curves for patients based on survival tree analysis.
doi:10.1371/journal.pone.0124471.g003
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proportional hazard regression model. Comparing to node 1 patients, the significant or border-
line significant higher recurrence risks were still observed in node 2 and node 3 patients for
both sub-cohort analyses. The significant P for trend tested in our survival tree models sug-
gested a potential clinical significance of our study for predicting early HCC recurrence (S3
Table).
Discussion
In the present study, we evaluated the associations of potential functional SNPs in the genes en-
coding TCA cycle key enzymes (SDH, FH and IDH) with the recurrence of HCC. Our study
identified 7 SNPs in SDHC, SDHD, FH, and IDH2 genes to be significantly associated with
HCC overall recurrence and early recurrence. Significant cumulative effects by a combination
of significant individual risk genotypes were observed in overall and early recurrence analyses.
Further stratified analysis suggested that the number of risk genotypes may modify the protec-
tive effect conferred by TACE treatment. Finally, the survival tree analysis revealed that SNP
rs10789859 in SDHD gene was the primary factor contributing to HCC recurrence in our pop-
ulation. To the best of our knowledge, our study for the first time reported the association be-
tween SNPs in genes of TCA cycle key enzymes and HCC recurrence risk.
It is well recognized that the alteration of cellular metabolism is a hallmark of cancer, con-
tributing to malignant transformation and to the growth and maintenance of tumors [13]. The
fundamental physiological roles of SDH, FH, and IDH as TCA cycle key metabolic enzymes
are to catalyze the oxidation of succinate to fumarate, hydration of fumarate to L-malate, and
oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) and CO2 in mitochondria, re-
spectively. A lot of studies have suggested that loss-of-function mutations in SDH complex and
FH lead to accumulation of omcometabolites such as succinate and fumarate, and oncogenic
mutations of IDH produces the oncometabolite 2-hydroxyglutarate (2-HG), which provides
strong evidence to link abnormal metabolism with cancers [8,14–18]. In our study, 5 signifi-
cant SNPs were located in the predicted functional transcript factor binding sites of the corre-
sponding genes, 1 SNP at the potential miRNA binding site, and 1 SNP in mRNA splicing site,
suggesting that these genetic variations may influence the expression level of the metabolic en-
zymes, and thus alter the metabolite profiling and contribute to HCC progression. In addition
to amino acid changes by SNPs in genes’ coding regions, SNPs in non-coding regions also di-
rectly alter gene functions through various mechanisms such as changing transcription activity,
mRNA processing, and the affinity of miRNA binding activity [19]. However, specific mecha-
nisms by which the significant SNPs affect the enzyme expression and functions are needed to
be further investigated.
Although surgical resection is the most effective curative treatment for HCC and markedly
improves the prognosis of HCC patients, the high recurrence rate (50%-70% at 5 years) remains
a major challenge in HCC therapy [3,20]. Early HCC recurrence defined as recurrence within 2
years after surgery is mainly related to local invasion and intrahepatic metastasis; whereas late
recurrence, occurring beyond 2 years after surgery, is mainly related to de novo tumor formation
[21,22]. It has been reported that the intrahepatic recurrence accounts for 70%-100% of the re-
current cases after surgical resection [23,24]. In our study, we demonstrated that SNPs in genes
encoding TCA cycle key enzymes were significantly associated with early HCC recurrence.
More interestingly, the stratified analysis showed that the loco-regional therapy of TACE had
significantly improved early HCC recurrence free survival in patients carrying with no less than
2 risk genotypes, but no significant result was observed in patients with less than 2 risk geno-
types. Concordantly, our previous studies have identified some single genetic polymorphisms
which are significantly associated with TACE treatment response in unresectable HCC patients
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[25,26]. Together, our study suggests that it may have clinical significance to incorporate these
SNPs into the current tumor staging systems for the prognosis assessment and tailored treat-
ment decision of HCC patients, once our finding is validated. In addition, we did not identify
any SNP to be associated with late HCC recurrence. However, we cannot rule out the possibility
of false negative results due to the small number of late recurrence events (n = 21) in our popu-
lation. Further studies with larger population are warranted to investigate the association be-
tween the SNPs in genes encoding TCA cycle key enzymes and HCC late recurrence.
Cancer is a complex disease involved by multiple factors and their interactions could affect the
clinical outcomes [27]. Therefore, we conducted survival tree analysis to observe the higher order
gene-gene interactions among SNPs in genes encoding TCA cycle key enzymes and their effects
on early recurrence in HCC patients. We found that SNP rs10789850 in SDHD gene as the prima-
ry split in the survival tree analysis exhibited the strongest influence on HCC patients’ early recur-
rence risk. Human SDHD gene encodes the small subunit of cytochrome b in mitochondrial
succinate-ubiquinone oxidoreductase [28]. Mutations in SDHD gene has been initially reported to
be associated with hereditary paraganglioma and SDHD has been suggested to play a role as tumor
suppressor [29]. Subsequently, the reduced protein expression and loss of heterozygosity of SDHD
gene have been identified in colorectal and gastric cancers [30]. In comparison, our study for the
first time reported that SNPs in SDHD gene are associated with HCC prognosis. However, the un-
derlying mechanism of how SDHD plays a role in HCC recurrence needs to be further examined.
Conclusions
Our study demonstrates that genetic variations in genes encoding TCA cycle key enzymes are
significantly associated with the early recurrence of HCC after surgical resection in a hospital-
based Chinese patient cohort. Further functional studies are warranted to reveal the underlying
mechanism.
Supporting Information
S1 Fig. Heatmap of linkage disequilibrium (LD) among the selected SNPs. The red
box indicated a strong LD coefficient of r2>0.8.
(TIF)
S2 Fig. Association of risk genotypes and HCC early recurrence by stratified analysis. A)
Stratified by TACE treatment, B) Stratified by tumor stage.
(TIF)
S1 Table. Information of SNPs and genotyping results.
(XLS)
S2 Table. Association of risk genotypes with early recurrence in HCC patients stratified by
patients’ characteristics.
(XLS)
S3 Table. Validation of survival tree analysis in early recurrence HCC.
(XLS)
Author Contributions
Conceived and designed the experiments: JX SWHY. Performed the experiments: XZ YW. An-
alyzed the data: YC XY. Contributed reagents/materials/analysis tools: JA XY HZ. Wrote the
paper: SW YW YC.
SNPs in TCA Genes and Early Recurrence of HCC
PLOSONE | DOI:10.1371/journal.pone.0124471 April 20, 2015 10 / 12
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin.
2011; 61: 69–90. doi: 10.3322/caac.20107 PMID: 21296855
2. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcino-
ma: current management and perspectives for the future. Ann Surg. 2011; 253: 453–469. doi: 10.1097/
SLA.0b013e31820d944f PMID: 21263310
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379: 1245–1255. doi: 10.1016/
S0140-6736(11)61347-0 PMID: 22353262
4. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular
carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005; 41: 707–716.
PMID: 15795889
5. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular
invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology.
2009; 137: 850–855. doi: 10.1053/j.gastro.2009.06.003 PMID: 19524573
6. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends
Mol Med. 2011; 17: 641–649. doi: 10.1016/j.molmed.2011.06.001 PMID: 21764377
7. Cardaci S, Ciriolo MR. TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. Int
J Cell Biol. 2012; 2012: 161837. doi: 10.1155/2012/161837 PMID: 22888353
8. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH
predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.
Nat Genet. 2002; 30: 406–410. PMID: 11865300
9. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, YuanW, et al. IDH1 and IDH2 mutations in glio-
mas. N Engl J Med. 2009; 360: 765–773. doi: 10.1056/NEJMoa0808710 PMID: 19228619
10. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial
dysfunction and cancer. Oncogene. 2006; 25: 4675–4682. PMID: 16892081
11. Fukuda H, Ebara M, OkuyamaM, Sugiura N, YoshikawaM, Saisho H, et al. Increased metabolizing ac-
tivities of the tricarboxylic acid cycle and decreased drug metabolism in hepatocellular carcinoma. Car-
cinogenesis. 2002; 23: 2019–2023. PMID: 12507924
12. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond.
Nat Rev Cancer. 2003; 3: 912–920. PMID: 14740638
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–674. doi: 10.
1016/j.cell.2011.02.013 PMID: 21376230
14. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012; 12: 685–698. doi: 10.1038/nrc3365
PMID: 23001348
15. Bardella C, Pollard PJ, Tomlinson I. SDHmutations in cancer. Biochim Biophys Acta. 2011; 1807:
1432–1443. doi: 10.1016/j.bbabio.2011.07.003 PMID: 21771581
16. Yen KE, Bittinger MA, Su SM, Fantin VR. Cancer-associated IDHmutations: biomarker and therapeutic
opportunities. Oncogene. 2010; 29: 6409–6417. doi: 10.1038/onc.2010.444 PMID: 20972461
17. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.
Cancer Cell. 2012; 21: 297–308. doi: 10.1016/j.ccr.2012.02.014 PMID: 22439925
18. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism with cancer. J Clin Invest.
2013; 123: 3652–3658. doi: 10.1172/JCI67228 PMID: 23999438
19. Chamary JV, Parmley JL, Hurst LD. Hearing silence: non-neutral evolution at synonymous sites in
mammals. Nat Rev Genet. 2006; 7: 98–108. PMID: 16418745
20. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor por-
tal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;
134: 1908–1916. doi: 10.1053/j.gastro.2008.02.091 PMID: 18549877
21. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contrib-
uting to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.
J Hepatol. 2003; 38: 200–207. PMID: 12547409
22. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed
tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359: 1995–2004. doi: 10.1056/
NEJMoa0804525 PMID: 18923165
23. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepa-
tocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214: 114–117. PMID: 1714267
24. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recur-
rence after resection of hepatocellular carcinoma. Ann Surg. 2000; 232: 10–24. PMID: 10862190
SNPs in TCA Genes and Early Recurrence of HCC
PLOSONE | DOI:10.1371/journal.pone.0124471 April 20, 2015 11 / 12
25. Yu X, Ge N, Guo X, Shen S, Liang J, Huang X, et al. Genetic variants in the EPCAM gene is associated
with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein
tumor thrombus. PLoS One. 2014; 9: e93416. doi: 10.1371/journal.pone.0093416 PMID: 24718422
26. Yuan P, Wang S, Zhou F, Wan S, Yang Y, Huang X, et al. Functional polymorphisms in the NPAS2
gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepato-
cellular carcinoma patients. Cancer Sci. 2014; 105: 825–832. doi: 10.1111/cas.12428 PMID: 24754267
27. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases.
Hum Hered. 2003; 56: 73–82. PMID: 14614241
28. Hirawake H, Taniwaki M, Tamura A, Amino H, Tomitsuka E, Kita K. Characterization of the human
SDHD gene encoding the small subunit of cytochrome b (cybS) in mitochondrial succinate-ubiquinone
oxidoreductase. Biochim Biophys Acta. 1999; 1412: 295–300. PMID: 10482792
29. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in
SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287: 848–851.
PMID: 10657297
30. HabanoW, Sugai T, Nakamura S, Uesugi N, Higuchi T, Terashima M, et al. Reduced expression and
loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncol Rep. 2003; 10:
1375–1380. PMID: 12883710
SNPs in TCA Genes and Early Recurrence of HCC
PLOSONE | DOI:10.1371/journal.pone.0124471 April 20, 2015 12 / 12
